Compare HELP & NGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HELP | NGEN |
|---|---|---|
| Founded | N/A | 2017 |
| Country | Canada | Canada |
| Employees | 50 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 281.4M | 317.6M |
| IPO Year | N/A | N/A |
| Metric | HELP | NGEN |
|---|---|---|
| Price | $4.92 | $3.66 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $95.00 | N/A |
| AVG Volume (30 Days) | ★ 1.0M | 94.7K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.09 | $3.73 |
| 52 Week High | $8.55 | $5.93 |
| Indicator | HELP | NGEN |
|---|---|---|
| Relative Strength Index (RSI) | 35.45 | 33.47 |
| Support Level | N/A | N/A |
| Resistance Level | $7.28 | $4.44 |
| Average True Range (ATR) | 0.65 | 0.26 |
| MACD | -0.24 | -0.01 |
| Stochastic Oscillator | 1.75 | 3.85 |
Helus Pharma Inc is a clinical-stage pharmaceutical company developing proprietary novel serotonergic agonists (NSAs), which are synthetic molecules designed to activate serotonin pathways associated with neuroplasticity. These compounds are being investigated for potential use in the treatment of depression, anxiety, and other mental health conditions, areas where there is an unmet medical need. It aims to provide treatments designed for mental health disorders. The company is currently developing HLP003, a proprietary NSA, in Phase 3 clinical development for the adjunctive treatment of substantial depressive disorder. It operates in Canada, the United States, the United Kingdom, and Ireland.
NervGen Pharma Corp is a clinical-stage biotech company. The company's principal business activity is the discovery, development, and commercialization of pharmaceutical treatments that enable the nervous system to repair itself following damage, whether due to injury or disease. The company's initial target indication is spinal cord injury. The company's pipeline products include NVG-291 and NVG-300.